🎗️ OncologyOne single-dose 225 mg strength gemcitabine intrave

    Inlexzo

    gemcitabine intravesical

    INLEXZO treats adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.

    Form

    One single-dose 225 mg strength gemcitabine intrave

    Uses

    1

    Side effects

    4

    Category

    Oncology

    01

    What is Inlexzo used for?

    • INLEXZO is indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BC
    02

    gemcitabine intravesical side effects

    Common side effects of gemcitabine intravesical include:

    Urinary frequency
    Urinary tract infection
    Dysuria
    Micturition urgency
    CommonModerateLess common
    03

    gemcitabine intravesical warnings & precautions

    • Risks in Patients with Perforated Bladder : Evaluate the bladder before the intravesical insertion of INLEXZO.
    • Do not administer to patients with a perforated bladder or in whom the integrity of the bladder mucosa has been compromised.
    • ( 4 , 5.1 ) Risk of Metastatic Bladder Cancer with Delayed Cystectomy : Delaying cystectomy can lead to the development of metastatic bladder cancer,

    Loading FDA data…

    04

    Frequently asked questions

    05

    Related medications

    Share

    Share this drug info.

    Help friends and family understand Inlexzo in plain language.

    Disclaimer: This information is sourced from the FDA openFDA database and is provided for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before starting or changing medication.